Literature DB >> 16098073

Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.

Takanori Teshima1, Keitaro Matsuo, Kosei Matsue, Fumio Kawano, Shuichi Taniguchi, Masamichi Hara, Kazuo Hatanaka, Mitsune Tanimoto, Mine Harada, Shinji Nakao, Yasunobu Abe, Atsushi Wake, Tetsuya Eto, Yoshinobu Takemoto, Masahiro Imamura, Satoshi Takahashi, Yoji Ishida, Yoshinobu Kanda, Masaharu Kasai, Yoichi Takaue.   

Abstract

The impact of human leucocyte antigen (HLA) incompatibility between donor and recipient on graft-versus-host disease (GVHD) and graft failure after reduced-intensity conditioning stem cell transplantation (RICT) remains to be elucidated. We retrospectively analysed outcome in 341 patients who underwent RICT from related donors for haematological malignancies. The overall cumulative incidence of grade II-IV acute GVHD (aGVHD) was 40% for all subjects; 39% in recipients with HLA-matched donors, 44% in those with one-locus-mismatched donors, and 50% in those with two- to three-loci-mismatched donors. In a Cox regression model adjusted for potential confounders, the tendency for grade II-IV aGVHD (P=0.01), chronic GVHD (cGVHD) (P=0.05) and graft failure (P=0.033) increased with HLA disparity. Use of peripheral blood grafts instead of marrow was a risk factor for cGVHD. Use of antithymocyte globulin was associated with reduced aGVHD and cGVHD. Overall survival (OS) in recipients of two- to three-loci-mismatched RICT at 2 years (18%) was significantly worse than that in patients who received one-locus-mismatched RICT (51%) and HLA-matched RICT (48%) (P<0.0001). A two- to three-loci mismatch was identified as an independent risk factor for OS (P<0.001), but there was no significant difference in OS between HLA-matched and one-locus-mismatched RICT. HLA incompatibility between the donor and recipient is an important risk factor for graft failure, aGVHD, cGVHD and OS after RICT. RICT from a one-locus-mismatched donor may represent an effective alternative approach in patients with high-risk malignancies who lack HLA-matched related donors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098073     DOI: 10.1111/j.1365-2141.2005.05632.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning.

Authors:  M Koyama; D Hashimoto; K Nagafuji; T Eto; Y Ohno; K Aoyama; H Iwasaki; T Miyamoto; G R Hill; K Akashi; T Teshima
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

2.  Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft.

Authors:  N Epperla; M Pasquini; K Pierce; W R Drobyski; J D Rizzo; M M Horowitz; W Saber; K Zellner; S Ramirez; K Bartz; R V Raj; P N Hari; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2016-08-01       Impact factor: 5.483

Review 3.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

Review 4.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

5.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Authors:  Simrit Parmar; Borje S Andersson; Daniel Couriel; Mark F Munsell; Marcelo Fernandez-Vina; Roy B Jones; Elizabeth J Shpall; Uday Popat; Paolo Anderlini; Sergio Giralt; Amin Alousi; Pedro Cano; Doyle Bosque; Chitra Hosing; Leandro de Padua Silva; Michael Westmoreland; J Kyle Wathen; Donald Berry; Richard E Champlin; Marcos J de Lima
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single japanese institution.

Authors:  Yoshihiro Inamoto; Yachiyo Kuwatsuka; Taku Oba; Seitaro Terakura; Kyoko Sugimoto; Akane Tsujimura; Taro Takahashi; Takahiko Yasuda; Koichi Miyamura; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

7.  A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.

Authors:  Jiro Inagaki; Reiji Fukano; Maiko Noguchi; Jun Okamura
Journal:  Int J Hematol       Date:  2017-02-15       Impact factor: 2.490

8.  Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.

Authors:  Sung-Won Kim; Keitaro Matsuo; Takahiro Fukuda; Masamichi Hara; Kosei Matsue; Shuichi Taniguchi; Tetsuya Eto; Mitsune Tanimoto; Atsushi Wake; Kazuo Hatanaka; Shinji Nakao; Yoji Ishida; Mine Harada; Atae Utsunomiya; Masahiro Imamura; Yoshinobu Kanda; Kazutaka Sunami; Fumio Kawano; Yoichi Takaue; Takanori Teshima
Journal:  Int J Hematol       Date:  2008-09-17       Impact factor: 2.490

9.  Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.

Authors:  H Nakasone; T Fukuda; J Kanda; T Mori; S Yano; T Kobayashi; K Miyamura; T Eto; H Kanamori; K Iwato; N Uchida; S Mori; T Nagamura-Inoue; T Ichinohe; Y Atsuta; T Teshima; M Murata
Journal:  Bone Marrow Transplant       Date:  2014-12-22       Impact factor: 5.483

10.  Role of HLA in Hematopoietic Stem Cell Transplantation.

Authors:  Meerim Park; Jong Jin Seo
Journal:  Bone Marrow Res       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.